MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$22,255K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Stock-based compensation expense
Depreciation and amortization
Others
Negative Cash Flow Breakdown
Net loss
Payment of debt and equity offer...
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-16,229
-12,266
-14,646
-24,320
Stock-based compensation expense
871
689
1,692
882
Depreciation and amortization
631
252
5
16
Non-cash lease expense
72
71
69
199
Loss on disposal of property and equipment
-
-
0
0
Change in fair value of warrant and conversion option liabilities
-615
91
4,017
-517
Prepaid expenses and other current assets
3,907
-2,054
-841
-1,606
Other assets
833
-64
0
0
Accounts payable
-1,434
1,700
-443
91
Accrued expenses and other current liabilities
-589
-1,300
1,808
-4,310
Deferred revenue
-
-
0
0
Other liabilities
-87
-87
201
-518
Net cash used in operating activities
-22,120
-8,732
-6,456
-26,871
Purchases of property and equipment
135
10
-
-
Net cash used in investing activities
-135
-10
-
-
Proceeds from exercise of pre-funded warrants
-
-
40
-
Proceeds from issuance of common stock and warrants, gross
69,000
-
-
-
Proceeds from exercise of common stock options
-
-
5
0
Proceeds from issuance of common stock and warrants
-
-
50,000
-
Proceeds from debt, gross
0
14,146
-
-
Proceeds from issuance of common stock related to employee stock purchase plan
2
-
22
3
Repayment of debt
0
0
841
1,216
Payment of debt and equity offering costs
4,532
220
3,701
-
Tax withholding payments on restricted stock units
0
10
831
0
Net cash provided by (used in) financing activities
64,470
13,916
44,694
-1,213
Net increase (decrease) in cash, cash equivalents, and restricted cash
42,215
5,174
38,238
-28,084
Cash, cash equivalents, and restricted cash at beginning of period
54,116
48,942
16,422
16,422
Cash, cash equivalents, and restricted cash at end of period
96,331
-
-
-
Cash and cash equivalents
96,295
-
-
-
Restricted cash, long-term (included in other assets)
36
-
-
-
Total cash, cash equivalents and restricted cash
96,331
54,116
48,942
10,704
Cash paid for interest on term loan
623
-
-
-
Allocation of debt to warrant liability for warrant and embedded conversion option
7,566
-
-
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock and...
$69,000K
Proceeds from issuance of
common stock related to...
$2K
Net cash provided by
(used in) financing...
$64,470K
Canceled cashflow
$4,532K
Net increase
(decrease) in cash, cash...
$42,215K
Canceled cashflow
$22,255K
Payment of debt and
equity offering costs
$4,532K
Stock-based compensation
expense
$871K
Depreciation and
amortization
$631K
Non-cash lease expense
$72K
Net cash used in
operating activities
-$22,120K
Net cash used in
investing activities
-$135K
Canceled cashflow
$1,574K
Net loss
-$16,229K
Prepaid expenses and
other current assets
$3,907K
Accounts payable
-$1,434K
Other assets
$833K
Purchases of property and
equipment
$135K
Change in fair value of
warrant and conversion...
-$615K
Accrued expenses and
other current...
-$589K
Other liabilities
-$87K
Buy us a coffee
SPRUCE BIOSCIENCES, INC. (SPRB)
SPRUCE BIOSCIENCES, INC. (SPRB)